220 related articles for article (PubMed ID: 23823605)
21. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study.
Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kanoh H
Ther Apher Dial; 2014 Jun; 18 Suppl 2():24-32. PubMed ID: 24975892
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy.
Fukagawa M; Kasuga H; Joseph D; Sawata H; Junge G; Moore A; Akiba T
Clin Exp Nephrol; 2014 Feb; 18(1):135-43. PubMed ID: 23670305
[TBL] [Abstract][Full Text] [Related]
23. Prevention and treatment of hyperphosphatemia in chronic kidney disease.
Vervloet MG; van Ballegooijen AJ
Kidney Int; 2018 May; 93(5):1060-1072. PubMed ID: 29580635
[TBL] [Abstract][Full Text] [Related]
24. Lower serum fibroblast growth factor-23 levels may suggest malnutrition in maintenance haemodialysis patients.
Mizuiri S; Nishizawa Y; Yamashita K; Ono K; Oda M; Usui K; Shigemoto K
Nephrology (Carlton); 2014 Sep; 19(9):568-73. PubMed ID: 24947687
[TBL] [Abstract][Full Text] [Related]
25. Physical function at the time of dialysis initiation is associated with subsequent mortality.
Inaguma D; Tanaka A; Shinjo H
Clin Exp Nephrol; 2017 Jun; 21(3):425-435. PubMed ID: 27392911
[TBL] [Abstract][Full Text] [Related]
26. CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis.
Block GA; Kilpatrick RD; Lowe KA; Wang W; Danese MD
Clin J Am Soc Nephrol; 2013 Dec; 8(12):2132-40. PubMed ID: 24052218
[TBL] [Abstract][Full Text] [Related]
27. Mortality in hospitalized chronic kidney disease patients starting unplanned urgent haemodialysis.
Panocchia N; Tazza L; Di Stasio E; Liberatori M; Vulpio C; Giungi S; Lucani G; Antocicco M; Bossola M
Nephrology (Carlton); 2016 Jan; 21(1):62-7. PubMed ID: 26173588
[TBL] [Abstract][Full Text] [Related]
28. Hypophosphatemia: nutritional status, body composition, and mortality in hemodialysis patients.
Garagarza C; Valente A; Caetano C; Oliveira T; Ponce P; Silva AP
Int Urol Nephrol; 2017 Jul; 49(7):1243-1250. PubMed ID: 28265965
[TBL] [Abstract][Full Text] [Related]
29. Phosphate binders in moderate chronic kidney disease: where do we stand?
Bellasi A; Cozzolino M; Adragao T; Di Iorio B; Russo D
J Nephrol; 2013; 26(6):993-1000. PubMed ID: 23543481
[TBL] [Abstract][Full Text] [Related]
30. Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients.
Cervelli MJ; Shaman A; Meade A; Carroll R; McDonald SP
Nephrology (Carlton); 2012 Jul; 17(5):458-65. PubMed ID: 22471559
[TBL] [Abstract][Full Text] [Related]
31. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.
Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
Nephrol Dial Transplant; 2009 Sep; 24(9):2792-6. PubMed ID: 19395730
[TBL] [Abstract][Full Text] [Related]
32. Conjoint effects of serum calcium and phosphate on risk of total, cardiovascular, and noncardiovascular mortality in the community.
Larsson TE; Olauson H; Hagström E; Ingelsson E; Arnlöv J; Lind L; Sundström J
Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):333-9. PubMed ID: 19948843
[TBL] [Abstract][Full Text] [Related]
33. Serum phosphate level at initiation of dialysis is associated with all-cause mortality: a multicenter prospective cohort study.
Owaki A; Inaguma D; Aoyama I; Inaba S; Koide S; Ito E; Takahashi K; Hayashi H; Hasegawa M; Yuzawa Y;
Ren Fail; 2018 Nov; 40(1):475-482. PubMed ID: 30153079
[TBL] [Abstract][Full Text] [Related]
34. Educating your patient helps to control serum phosphate and also save 200 euros per patient.
Rodriguez-Palomares JR; Japaz Cancino MC; Blazquez Collado L; Fiallos Criollo R; Villabon Ochoa PM; Sanchez Heras M; Basterrechea MA; de Arriba de la Fuente G
Nefrologia; 2017; 37(1):103-105. PubMed ID: 27825657
[No Abstract] [Full Text] [Related]
35. Ten-year experience with sevelamer and calcium salts as phosphate binders.
Raggi P; Vukicevic S; Moysés RM; Wesseling K; Spiegel DM
Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S31-40. PubMed ID: 20089501
[TBL] [Abstract][Full Text] [Related]
36. Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk.
Toussaint ND; Pedagogos E; Tan SJ; Badve SV; Hawley CM; Perkovic V; Elder GJ
Nephrology (Carlton); 2012 Jul; 17(5):433-44. PubMed ID: 22574672
[TBL] [Abstract][Full Text] [Related]
37. Phosphate balance in ESRD: diet, dialysis and binders against the low evident masked pool.
Galassi A; Cupisti A; Santoro A; Cozzolino M
J Nephrol; 2015 Aug; 28(4):415-29. PubMed ID: 25245472
[TBL] [Abstract][Full Text] [Related]
38. Gut microbiota; an overlooked effect of phosphate binders.
Rahbar Saadat Y; Niknafs B; Hosseiniyan Khatibi SM; Ardalan M; Majdi H; Bahmanpoor Z; Abediazar S; Zununi Vahed S
Eur J Pharmacol; 2020 Feb; 868():172892. PubMed ID: 31870830
[TBL] [Abstract][Full Text] [Related]
39. Geographical variability of patient characteristics and treatment patterns affect outcomes for incident hemodialysis patients.
Martin-Malo A; Papadimitriou M; Cruz J; Bustamante J; Verbeelen D; Nony A; Vanholder R; Jacobson SH; Montenegro J; Hannedouche T; Wizemann V; Locatelli F;
J Nephrol; 2013; 26(1):119-28. PubMed ID: 22476964
[TBL] [Abstract][Full Text] [Related]
40. Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study.
Messa P; Cozzolino M; Brancaccio D; Cannella G; Malberti F; Costanzo AM; di Luzio Paparatti U; Festa V; Gualberti G; Mazzaferro S;
BMC Nephrol; 2015 Feb; 16():11. PubMed ID: 25886515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
